BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females

Trial Profile

BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 05 Apr 2017 Primary endpoint of change from baseline in the clinic 10-item montgomery-asberg depression rating scale (MADRS) total score for Botulinum toxin A 30 U vs. placebo has been met, according to results published in an Allergan media release.
    • 05 Apr 2017 Top-line results published in an Allergan media release
    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top